openPR Logo

Press Releases from Apeiron (6 total)

05-15-2017 | Health & Medicine
Apeiron

Marketing Approval for Children’s Cancer Immunotherapy in the EU: Outstanding …

May 8, 2017, The European Commission has granted marketing authorization for "Dinutuximab beta Apeiron", an antibody-based immunotherapy of the rare pediatric cancer neuroblastoma. Thanks to the Vienna-based Biotech company Apeiron Biologics AG ("Apeiron") patients in Europe are now offered an additional treatment option with a promising therapy – a result of a collaborative effort of management and employees, academic institutions, Austrian private investors, business angels as well as public and
10-05-2016 | Health & Medicine
APEIRON

Neuroblastoma: APEIRON Grants EUSA Pharma Global Rights to Immunotherapy

Vienna, Austria, 04 October 2016 – APEIRON Biologics AG grants EUSA Pharma, UK exclusive global commercialization rights to the oncology product ISQETTE®. ISQETTE® is an antibody-based immunotherapy with orphan drug designation for the treatment of pediatric neuroblastoma. The therapy has been developed by APEIRON together with an academic network including the St. Anna Children's Cancer Research Institute in Vienna. APEIRON Biologics AG, a private biotech company based in Vienna, Austria, developing
12-17-2012 | Health & Medicine
Apeiron

Apeiron Biologics Establishes Biotech-Spinoff Attoquant Diagnostics

APEIRON Biologics AG (Apeiron) today announced the launch of Attoquant Diagnostics GmbH (Attoquant) as a subsidiary. Attoquant will globally commercialize its already successfully marketed peptide analytics service RAS-Fingerprint™ and further develop the underlying platform technology. Vienna-based biotech company APEIRON Biologics AG (Apeiron) today announced the establishment of a subsidiary that will globally commercialize the peptide analytics service RAS-Fingerprint™ which has been developed by Apeiron and already marketed successfully. Attoquant Diagnostics GmbH

Experienced Venture Capitalist/Pharma Manager Joins Apeiron`s Business Developme …

Vienna (Austria), 10 January 2011 - APEIRON Biologics AG (Apeiron) today announced that Patrick Burgermeister, a seasoned venture capital and pharma manager will play a leading role in the company's business development activities. He will be engaged in identification and evaluation of new projects, in-licensing/out-licensing activities, portfolio assessment and sourcing new financing opportunities. Patrick Burgermeister has a dual background in business administration and molecular biology and brings in extensive industry
11-06-2010 | Health & Medicine
Apeiron

Apeiron Acquires Rights To New Clinical Stage Project:

License for therapeutic enzyme for treatment of inflammatory conditions marks first step of project portfolio build-up APEIRON Biologics AG (Apeiron) today announced that, as part of its effort to broaden its current project portfolio, it has concluded an agreement with Polymun Scientific GmbH (Polymun) granting Apeiron exclusive rights to recombinant human Super Oxide Dismutase (SOD). SOD, a naturally occurring enzyme with important, antioxidant properties, has so far been under development as

Apeiron Nominated for the Most Important European Biotechnology Award

Vienna-based biotech company Apeiron Biologics AG has been nominated as one of three finalists for the European Biotechnica Award. The Biotechnica Award, which is presented by Deutsche Messe AG as part of the sector's leading trade fair, is regarded as Europe's most prestigious biotech award. Apeiron is the only unlisted finalist. The company first caught the attention of industry insiders in January 2010 when it signed a licensing agreement with